Selective p38-MAPK inhibitor that targets a subset of inflammatory macrophage genes (IC50 value 2.5 nM for p38α, and no IC50 values  below 5 μM, except for JNK1 (5 µM)). When used with dexamethasone, SB 706504 causes effective suppression of these genes without affecting transcription of a subset of LPS-regulated genes, including IL-1β, IL-18, and CCL5 (genes involved in the pathogenesis of COPD). Furthermore, SB 706504 reduces TNFα, GM-CSF, and IL-6 production from LPS-stimulated COPD macrophages, with less effect on IL-8 production.

 KEYWORDS: SB 706504 | Supplier | p38 MAPK inhibitor | Axon Medchem | Axon 2444 | PCG | SB706504 | CAS [911110-38-8] | MAPK (p38) | Inhibitor | COPD | macrophage | inflammation | LPS | TNFα | cytokines